GTx Submits Clinical Hold CRL for Its Phase II Clinical Study of Capesaris Secondary Hormonal Therapy of Advanced Prostate Cancer

GTx announced that it has submitted to the FDA a complete response to the FDA’s letter regarding the previously announced full clinical hold of its clinical trials evaluating Capesaris (GTx-758) for primary (first line hormonal) androgen deprivation therapy for advanced prostate cancer and secondary (second line) hormonal therapy.
MarketWatch